ABSTRACT
INTRODUCTION
Recurrent miscarriage (RM) is a major obstetric problem that is challenging for both: the patients as well as the clinicians. Approximately 3% of women in reproductive age experience recurrent pregnancy loss [1, 2] . The etiology is multifactorial and includes chromosomal abnormalities, uterine anatomical pathologies, endocrine dysfunctions, maternal autoimmune disorders, acquired or inherited thrombophilia and environmental causes [3] . Despite the availability of diagnostic methods such as hysteroscopy, hysterosalpingography, antiphospholipid antibody testing or parental karyotyping, the underlying pathology remains unidentified in 50% of cases which are defined as unexplained RMs [4] . Multiple pregnancy loss is also a risk factor for intrauterine growth restriction (IUGR), preterm delivery and fetal abnormalities [5] . Finally, a cohort study reports www. journals.viamedica.pl/ginekologia_polska that patients with recurrent miscarriage represent a population that is at high risk for obstetric complications that require a close surveillance during the antenatal period [5, 6] .
Increased homocysteine concentration in maternal circulation is associated with unexplained RM. Hyperhomocysteinemia was detected in approximately 30% of RM patients [7, 8] . Since 5' ,10'-methylenetetrahydrofolate reductase (MTHFR) enzyme encoded by the MTHFR gene is necessary for the conversion of homocysteine to methionine, the reduction in enzyme activity results in a mild elevation of blood homocysteine levels [11] . The single nucleotide polymorphism of C677T and A1298C are the most commonly identified forms of MTHFR gene polymorphism. Patients homozygous for MTHFR C677T showed about 30% of normal enzyme activity while heterozygosity demonstrates 65% of normal enzyme activity. In contrast, such reduction in enzyme activity in women with MTHFR A1298C polymorphism was not demonstrated [9, 10] . It would be reasonable then to assume that the A1298C type of polymorphism does not influence the homocysteine levels, hence it should not be linked to unexplained RM. Indeed, a recent meta-analysis has found that there is no relation between MTHFR A1298C polymorphism and unexplained recurrent pregnancy loss. However, it has also been found that the MTHFR C677T type was a contributor for recurrent pregnancy loss but in East Asians only [12, 13] . The debate on MTHFR gene polymorphism and unexplained RM remains elusive.
There is also no consensus about the use of low molecular weight heparin (LMWH) for preventing miscarriages. In recent Cochrane meta-analysis the authors did not recommend anticoagulants in RM patients beyond those complicated with inherited thrombophilia. They also suggested that pregnancy complications like preterm delivery, preeclampsia, IUGR and congenital abnormalities were not significantly affected by the use of aspirin or LMWH [14] . Despite this, empirical therapy for unexplained RM patients in form of a low dose aspirin and prophylactic doses of LMWH has been a widespread clinical practice in several clinics around Turkey [15] .
OBJECTIVES
We performed a retrospective study to evaluate the impact of LMWH on obstetric outcomes of recurrent miscarriage patients complicated with MTHFR gene polymorphism in our tertiary referral hospital in eastern Turkey.
MATERIAL AND METHODS
This single center retrospective study was conducted at Yuzuncu Yıl University Medical Faculty, Obstetrics and Gynecology clinic in Van, Turkey. This study was approved by the institutional ethics committee of Yuzuncu Yıl University. Medical records of 249 women with a history of recurrent miscarriage were reviewed. They were tested for inherited thrombophilia between January 2010 and June 2015 in our tertiary referral center. From among them 121 women aged 18-45 with MTHFR gene polymorphism were selected into the study population. The polymorphism composed of MTHFR C677T and A1298C gene homozygosity or heterozygosity and compound heterozygosity. The selected women were followed up at our obstetric unit during their pregnancy. The patients with anatomic, hormonal, chromosomal, infectious and autoimmune factors for recurrent miscarriage were excluded from the study. The laboratory genotyping of the MTHFR gene was performed by the Polymerase Chain Reaction which was performed by a Perkin Elmer 9600 and the profile consisted of an initial melting step of 2 min at 94°C; followed by 35 cycles of 30 s at 94°C, 30 s at 61°C, and 30 s at 72°C; and a final elongation step of 7 min at 72°C. The normal and mutant heterozygous or homozygous genotype profiles of each of the genes were determined using the enclosed Collector TM sheet. Patients were divided into two groups: Anticoagulant free group (Group A) (n: 68) and anticoagulant therapy group (Group B) (n: 53). The women in group A received only oral folic acid (5 mg/day) and iron (80 mg elementary iron/day, iron [II] sulphate) during their pregnancy. The women in group B received oral folic acid (5 mg/day), iron (80 mg elementary iron/day, iron [II] sulphate) and prophylactic dose of LMWH (enoxaparin 40 mg/day or bemiparin 3500 IU/day, subcutaneously). LMWH therapy was started between 6 th and 8 th week of pregnancy and continued until delivery. The primary outcome was live birth. Among secondary outcomes there were early-late miscarriages, stillbirths, preterm births, congenital anomalies, obstetric complications and short-term neonatal events. These pregnancy outcomes of the patients were reviewed from the hospital's medical records.
RM was described as three or more consecutive spontaneous pregnancy losses before 22 nd week of gestation (early or late miscarriage). All miscarriages were confirmed either by positive urine/serum HCG and sonography or histology of uterine curettage. Early miscarriage was defined as a pregnancy loss at < 12 weeks of gestation. Late miscarriage was defined as a pregnancy loss between 12 and 22 weeks of gestation. Stillbirth was defined as a pregnancy loss > 22 weeks of gestation. Intrauterine growth restriction (IUGR) was defined as a birthweight < 5 th percentile [16] . Severe preeclampsia was described as blood pressure > 160/110 mm Hg recorded at least 6 h apart and proteinuria > 5 gm in a 24-hour urine sample. In addition, any patient with cerebral or visual impairment, persistent epigastric pain, pulmonary edema or cyanosis was diagnosed with severe preeclampsia [17] .
Descriptive statistics for the studied variables (characteristics) were presented as Mean, Standard Deviation values. Continuous variables were compared among the two groups using Student T-test. Z-ratio test was used to examine the association between categorical variables. Statistical significance levels were set to 5%. (7/121) in the study and this rate was similar between each group (7.4% vs. 3.8% respectively, p: 0.465). The total congenital anomaly rate was 11.6% (14/121) in the study and congenital anomalies were more frequent in group A (17.6% vs. 3.8% respectively, p: 0.022). Group A involved 5 fetuses with neural tube defect, 3 fetuses with diaphragm hernia, 1 fetus with esophagus atresia, 2 fetuses with non-immune hydrops fetalis and 1 fetus with hypo plastic left ventricle syndrome. In group B, only 2 fetuses had neural tube defect.
The delivery and short term neonatal outcomes of the patients were shown in Table 2 . The total mean gestational age at birth was 33.81 ± 5.09 in the study. There were no significant differences between the groups in terms of gestational age at birth, delivery type, delivery complications (fetal distress, prolonged labor, placental abruption, severe preeclampsia and placenta previa), birthweight, Apgar scores and neonatal intensive care unit (NICU) admission. The total NICU admission rate was 19.0% (23/121) in the study. The total fetal distress, placental abruption and severe preeclampsia rates were as 17.4% (21/121), 5.0% (6/121) and 3.3% (4/121), respectively in the study.
DISCUSSION
The current study demonstrated that unexplained RM patients with MTHFR gene polymorphism, who received [18] . Similarly, the recent Cochrane review suggests that the live birth rate is not affected by LMWH treatment in unexplained RM patients [14] . In opposition to that stands a recent study from Turkey reporting positive effects of LMWH on live birth rate in recurrent miscarriage patients who used LMWH when compared to patients without LMWH treatment [15] . Our study in turn shows that LMWH improves the live birth rate among RM patients with MTHFR gene polymorphism. The apparent heterogeneity of study populations in these different clinical trials may be the origin for conflicting results. Furthermore, most of the studies mentioned above did not include women with MTHFR gene polymorphism [15, 18] . It is of vital importance that our study population is composed of selected groups of unexplained RM patients with different MTHFR gene polymorphisms.
Many previous studies reported that there were possible associations between MTHFR gene polymorphism (especially MTHFR C677T polymorphism) and fetal neural tube defects. However, MTHFR gene polymorphism is not the main factor behind such congenital malformations. Moreover, maternal blood homocysteine levels can also be altered by some genetic and environmental factors [7, 8] . Yet, the fetal neural tube defect rate in our study was 5.9% (7/121), which is higher than in the general population (0.5-2/1000) [19] .
RM is also associated with fetal anomalies [5] . Two clinical trials compared congenital abnormalities in RM patients and they reported similar rates between patients that did and did not receive LMWH [20, 21] . In our study, congenital abnormalities were more frequent in LMWH-free group (group A). Although our study did not intend to investigate this issue, we did not reveal any association between these abnormalities and LMWH. Hence, such observation cannot be explained by the usage of LMWH.
High levels of maternal homocysteine have been associated with preeclampsia and abruption of placenta [22, 23] . It has been established that hyperhomocysteinemia is a contributor to endothelial dysfunction in pregnancy [23] . In a recent meta-analysis it was demonstrated that MTHFR C677T polymorphism was associated with preeclampsia in Asian and white population while MTHFR A1298C polymorphism had no such association [26] . Also, events like necrosis, acute and chronic inflammation or vascular thrombosis are more prominent in the deciduae of RM patients compared with normal pregnancies [27] . These factors are possible causes of late pregnancy complications like preeclampsia, placental abruption and late pregnancy complications in RM [5, 26] . Some randomized controlled trials determined that LMWH is a preventive treatment for placenta mediated pregnancy complications [27, 28] . However, Martinelli et al. suggested that LMWH should not be routinely administered to prevent recurrence of placenta-mediated pregnancy complications [29] . Badawy et al. did not detect The present study has several limitations. The study is retrospective and small in sample size. We focused only on MTHFR gene polymorphism and the effects of anticoagulant use in RM patients without controlling for maternal folic acid and homocysteine concentrations. Also, we included all subgroups of MTHFR gene polymorphism, thus the heterogeneity of the study population may cause a potential bias. The clinicians advised different LMWH regimens to the patients according to their clinical experience, so we could not standardize the LMWH regimen. Some patients were administered enoxaparin and some bemiparin for LMWH prophylaxis.
CONCLUSIONS
Based on the available evidence, the association between MTHFR gene polymorphism and RM, as well as the usage of LMWH for preventing obstetric complications or empiric anticoagulation for unexplained RM, all remain debatable topics in the literature. However, in current clinical practice many obstetricians all around Turkey still use anticoagulation treatment modalities for the aforementioned clinical indications. The current indiscriminate use of LMWH for all RM patients in Turkey should be changed according to the evidence based guidelines. In our opinion, specific subgroups of RM patients might benefit from new treatment strategies. As a result of this study, despite a limited number of patients, we propose that anticoagulation therapy be preferred for improving live birth rate in unexplained RM patients complicated with MTHFR gene polymorphism only. We also call for further studies to discriminate the effect of LMWH on the live birth rate in specific subgroups of MTHFR gene polymorphism (homozygous vs. heterozygous). We also conclude that in our patients selected from eastern region of Turkey with MTHFR gene polymorphism, the routine use of low molecular weight heparin did not improve the late pregnancy complications.
